Navigation Links
Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
Date:10/30/2007

-----------------------------------------------------------

Revenue - - - - - - - -

-------------------------------------------------------------------------

Interest

income 319 359 268 286 320 335 292 160

-------------------------------------------------------------------------

Net

loss(3), 3,764 3,680 4,156 4,890 3,425 2,988 2,995 3,941

-------------------------------------------------------------------------

Basic and

diluted

loss per

common

share(3) $0.09 $0.09 $0.11 $0.13 $0.09 $0.08 $0.08 $0.12

-------------------------------------------------------------------------

Total

assets

(1),(4) 33,897 37,670 41,775 33,566 37,980 40,828 43,660 46,294

-------------------------------------------------------------------------

Total

cash

(2),(4) 28,191 31,533 35,681 27,614 31,495 34,501 37,687 40,406

-------------------------------------------------------------------------

Total

long-term

debt(5) - - - 150 150 150 150 150

-------------------------------------------------------------------------

Cash

dividends

declared

(6) Nil Nil Nil Nil Nil Nil Nil Nil

-------------------------------------------------------------------------

(1) Subsequent to the acquisition of Oncolytics Biotech Inc. by SYNSORB

in April 1999, we applied push down accounting. See note 2 to the

audited financial statements for 2006.

(2) Included in total cash are cash and cash equivalents plus short-term

investments.

(3) Included in net loss and loss per common share between September 2007

and October 2005 are quarterly stock based compensation expenses
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29

Related biology technology :

1. The state of global biotech: An Ernst & Young perspective
2. Olympics of biotechnology has international flavor
3. Biotech officials praise focus of new venture fund
4. Getting noticed in Genetown: Wisconsin biotech on display
5. Madison biotech NimbleGen files for IPO; one of states best-funded firms
6. Wisconsin biotech firm receives $107K NIH grant
7. Biotech executive books a career flight thats closer to home
8. Manufacturing partnership will move into biotech and biomedical spaces
9. Wisconsin wont get Georgia biotech without a fight
10. The 10 biggest events shaping biotech in 2006
11. Gala Biotech among companies sold for $3.3 billion
Post Your Comments:
*Name:
*Comment:
*Email: